Clinical Trials Logo

Clinical Trial Summary

Inhaled nitric oxide in patients with pulmonic valve insufficiency.


Clinical Trial Description

Pulmonic valve insufficiency (PI) is a well-defined problem after primary surgical repair of Tetralogy of Fallot (TOF). Though well-tolerated for years, long-term PI can lead to structural changes in the right ventricle, the sequelae of which include right heart failure, arrhythmia, and sudden cardiac death. The only current treatment for severe symptomatic PI is pulmonic valve replacement. We hypothesize that inhaled nitric oxide (iNO), a selective pulmonary vasodilator, can acutely decrease PI as assessed by cardiac magnetic resonance imaging (CMR). Methods: 22 consecutive patients with PI in the setting of corrected TOF or post pulmonic valve balloon valvuloplasty will undergo a clinically indicated CMR. Nitric oxide gas will be delivered via facemask through a specialized delivery device at 40ppm. After 5 minutes, flow velocity mapping and gradient echo sequences will be repeated to assess pulmonary regurgitant fraction, right ventricular volumes, and ejection fraction. Nitric oxide will be discontinued after acquisition of the last picture. Wilcoxon rank-sum for paired data will be used to assess effect of intervention. Significance: If decreasing pulmonary vascular resistance decreases PI, medical therapy with long-acting pulmonary vasodilators may be an attractive therapeutic option with the goal of delaying or even obviating pulmonic valve replacement. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00543933
Study type Interventional
Source The Cleveland Clinic
Contact
Status Terminated
Phase N/A
Start date October 2007
Completion date June 2010

See also
  Status Clinical Trial Phase
Completed NCT01356108 - Pulmonic Valve REplacement Multi-discIpline EMEA Registry
Completed NCT00834054 - Measurement of Lung Water by Transpulmonary Thermodilution in Lung Transplanted Patients N/A
Recruiting NCT05186415 - Contrast Enhanced Three Dimensional Echocardiographic Quantification of Right Ventricular Volumes in Repaired Congenital Heart Disease Phase 1/Phase 2